A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

por Hou, Jian, Du, Xin, Jin, Jie, Cai, Zhen, Chen, Fangping, Zhou, Dao-bin, Yu, Li, Ke, Xiaoyan, Li, Xiao, Wu, Depei, Meng, Fanyi, Ai, Huisheng, Zhang, Jingshan, Wortman-Vayn, Honeylet, Chen, Nianhang, Mei, Jay, Wang, Jianmin
Publicado 2013